Antimicrobial activity against Viridans streptococcus L2 with gyrA Ser114Gly, gyrB Ser494Thr and parC Ser52Gly, Asn91Asp mutation by broth dilution method
Antimicrobial activity against Viridans streptococcus L7 with gyrA Ser114Gly, gyrB Ser494Thr and parC Ser52Gly, Asn91Asp mutation by broth dilution method
Antimicrobial activity against Viridans streptococcus L16 with gyrA Ser114Gly, gyrB Ser494Thr and parC Ser52Gly, Asn91Asp mutation by broth dilution method
Antimicrobial activity against Viridans streptococcus L17 with gyrA Ser114Gly, gyrB Ser494Thr and parC Ser52Gly, Asn91Asp mutation by broth dilution method
Antimicrobial activity against Viridans streptococcus L18 with gyrA Ser114Gly, Asp142Asn, gyrB Ser494Thr and parE Ile460Val mutation by broth dilution method
Antimicrobial activity against Viridans streptococcus L19 with gyrA Ser114Gly, gyrB Ser494Thr, parC Ser52Gly, Asn91Asp and parE Ile460Val mutation by broth dilution method
Ratio of MIC for Streptococcus viridans group clinical isolate to MIC for Streptococcus viridans group clinical isolate in presence of 0.002% polysorbate 80